Cannabis Law Report

JULY 21, 2021

The study is expected to be the world’s first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia. The open-label Phase 2a clinical trial will evaluate the efficacy of TRYP-8802, an oral formulation of synthetic psilocybin, in tandem with psychotherapy for treating fibromyalgia.

Clinical Trials 105

Clinical Trials Chronic Pain Research and Development Treatment 105

NORML

DECEMBER 18, 2020

This study’s primary outcome supports the theory that cannabis should be [tested in clinical trials] as a potential therapeutic for PTSD.". The post Study: Long-Term Cannabis Use Associated with Reduced Symptoms in Patients with Post-Traumatic Stress appeared first on NORML.

Clinical Trials 246

Clinical Trials Patients Treatment Dispensary 246

NORML

DECEMBER 6, 2019

The transdermal application of plant-derived CBD reduces fascial pain in patients with temporomandibular disorders (TMD aka TMJ), according to clinical data published in the Journal of Clinical Medicine. Subjects receiving treatment reported no adverse effects.

Clinical Trials 108

Clinical Trials Patients CBD Therapy 108

NORML

MAY 21, 2019

” In observational models , patients with legal access to cannabis typically reduce or eliminate their use of opioids. In clinical models, CBD administration has been shown to reduce cravings for tobacco. CBD dosing has also been associated with reduced cravings for methamphetamine in preclinical models.

Clinical Trials 188

Clinical Trials CBD History Data 188

Cannabis Law Report

AUGUST 10, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today reported that its subsidiary Oravax Medical Inc. Oravax”), partially owned with its majority partner Oramed Pharmaceuticals Inc.

Clinical Trials 105

Clinical Trials Pharmaceutical Research and Development CBD 105

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Cannabis Law Report

DECEMBER 14, 2021

IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. The trial was conducted as a multiple ascending dose (MAD) study.

Clinical Trials 52

Clinical Trials Safety Data Patients 52

Cannabis Law Report

JUNE 29, 2021

We look forward to his expertise as we expand our mental health analytical platform and enter clinical trials. is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. ramps up to begin clinical trials by adding esteemed medical professional to its medical advisory board.

Clinical Trials 105

Clinical Trials Research and Development Data Patients 105

Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Clinical Trials 52

Clinical Trials Data Patients THC 52

CannaMD

MARCH 30, 2022

While there have yet to be conclusive clinical trials defining the benefits of cannabis for Parkinson’s disease, these results indicate that many patients are finding relief with marijuana. More than 70% of people with Parkinson’s disease use marijuana to treat their symptoms, according to a recent survey.

Patients 98

Patients Clinical Trials Cannabis Marijuana 98

Puff Puff Post

MARCH 10, 2020

InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. For more information, visit www.inmedpharma.com.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

APRIL 28, 2023

(“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, is pleased to announce that it has commenced a Phase II clinical trial for its proprietary […] (..)

Clinical Trials 52

Clinical Trials Pharmaceutical Patients Business 52

Cannabis Law Report

OCTOBER 26, 2021

The agreement between the two companies will see Procaps making IHL-42X for Incannex’s Phase 2, Phase 3, and open-label clinical trials. If these trials are successful and IHL-42X is approved for the market, Procaps will also make IHL-42X for patients.

Clinical Trials 52

Clinical Trials Sleep Medicine Pharmaceutical 52

Medical Marijuana Program Connection

MARCH 14, 2023

announced that the first patient has been enrolled in. The University of Nebraska Medical Center (UNMC) and ANANDA Scientific Inc. Read More

Clinical Trials 52

Clinical Trials Patients Treatment CBD 52

Cannabis Law Report

MARCH 30, 2019

In Japan, there are approximately 3,000 patients who suffer from Dravet Syndrome, and some 4,300 afflicted with Lennox-Gastaut. Japanese officials approve Epidiolex for clinical trials. It was primarily developed for the treatment of two severe forms of epilepsy — Dravet Syndrome and Lennox-Gastaut Syndrome.

Clinical Trials 45

Clinical Trials Research and Development Epilepsy Environment 45

SpeedWeed

FEBRUARY 18, 2021

The study was carried out by researchers in Israel, who looked at how inhaling herbal cannabis impacted ulcerative colitis patients over a period of eight weeks, with continued, steady, use. The patients also kept taking standard medication. The patients also kept taking standard medication. THC and Inflammation.

Clinical Trials 52

Clinical Trials Treatment Data THC 52

SpeedWeed

MAY 15, 2021

A first-of-its-kind Phase 3 clinical trial has found that MDMA-assisted therapy provided meaningful relief from PTSD symptoms in nearly 90 percent of study participants. For this study, researchers recruited 90 patients suffering from severe, chronic PTSD. Image via. This promising new study is helmed by Rick Doblin, Ph.D.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

The Cannigma

MARCH 18, 2021

Published in Nature Partner Journals and sponsored by the Parkinson’s Foundation, the study found that nearly 25% of Parkinson’s patients had used cannabis in the past six months, but that one in four of that group did not know what type or form of cannabis they used, and nearly half did not know their dosage. Of the 43.9% Altogether, 24.5%

Patients 141

Patients Clinical Trials Treatment Cannabis 141

CannaMD

JUNE 2, 2021

As the study authors stated: The wider availability [of marijuana] means Parkinson’s patients have more of an opportunity now to experiment with it as a potential means of controlling their symptoms. However, little is known about these patients’ thoughts and experiences related to cannabis, or its perceived effect on the disease’s symptoms.

Patients 105

Patients Clinical Trials Treatment Research and Development 105

The Joint Blog

NOVEMBER 8, 2020

According to a new study published in the journal Pain Medicine and epublished by the National Institute of Health, the daily use of marijuana oil is effective and well-tolerated among patients with fibromyalgia. On average patients received 3.6 Placebo controlled patients received no such benefit. mg of THC and 0.08

Clinical Trials 49

Clinical Trials Oil Therapy Marijuana 49

NORML

APRIL 30, 2020

.” The CDC’s interest in alternative methods of chronic pain management may be of particular significance to many medical cannabis patients. According to state-registry records, “Chronic pain is currently and historically the most common qualifying condition reported by medical cannabis patients (67.5

Chronic Pain 337

Chronic Pain Clinical Trials Data Patients 337

Otherside Farms

JANUARY 24, 2019

In San Francisco and New York City, the physician-led pediatric studies will assess the viability of a purified cannabidiol as an anti-seizure treatment among patients with various forms of epilepsy. Although both studies will enroll 25 patients initially, the U.S.

Clinical Trials 45

Clinical Trials Epilepsy Marijuana Pharmaceutical 45

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Medical Marijuana Program Connection

APRIL 4, 2023

Diabetic patients administered a sublingual spray containing CBD and THC show improvements in their blood sugar and cholesterol levels, according. Read More

Clinical Trials 52

Clinical Trials THC CBD Patients 52

The Cannigma

MARCH 25, 2021

In nursing school, I wrote my dissertation on the role of the nurse when caring for patients using cannabis therapeutically, knowing that nurses are often the first healthcare professional to whom patients disclose their cannabis use. I remain in awe of these patients to this day. Transfering nurses’ skills to cannabis medicine.

Patients 145

Patients Clinical Trials Medicine Events 145

Veriheal

MAY 12, 2021

In light of such, and the fact that cancer is a common qualifying condition for cannabis, this research team took to expanding the available basic information on cannabis in the cancer population in order to provide clinical trial designers with better information needed for planned studies. Cancer Patients Experience Less Severe Pain.

Patients 98

Patients Consumption Clinical Trials Education 98

MMJ Recs

AUGUST 1, 2024

While antiretroviral therapy (ART) has transformed HIV/AIDS from a fatal diagnosis to a manageable chronic condition, patients often endure chronic pain, nausea, appetite loss, and psychological distress. Medical marijuana for HIV/AIDS offers a promising complementary treatment for patients.

Patients 52

Patients Chronic Pain Marijuana Sleep 52

CannaTech

SEPTEMBER 23, 2019

The acceptance of medical cannabis by clinicians, researchers and government bodies is fairly universal, and patients have benefited from widespread access to full-spectrum cannabis in flower and oil form. Israel’s approach to cannabis has contributed to reducing stigma and increasing access for patients around the world.

Patients 79

Patients Policy Clinical Trials Research and Development 79

Puff Puff Post

MARCH 10, 2020

InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. For more information, visit www.inmedpharma.com.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

OCTOBER 6, 2021

(NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce that it has signed an agreement to begin scientific clinical trials globally.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

JUNE 19, 2022

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials. Beckley Psytech aims to track and improve patient experience through an integrated, digitally-assisted treatment model. June 14, 2022 02:00 AM Eastern Daylight Time.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

Veriheal

JUNE 29, 2021

This Act permits individuals that have been diagnosed with life-threatening conditions or diseases that have exhausted all other approved treatment and therapeutic options that are also unable to participate in clinical trials the ability to access certain treatments that would otherwise be unapproved for access. A Push by Patients.

Therapy 64

Therapy DEA Patients Clinical Trials 64

LifeCannMD

JULY 3, 2024

Top 6 ways that Medical Marijuana helps patients with PTSD or other anxiety and mood disorders: Anxiety and Fear Reduction: THC (tetrahydrocannabinol) and CBD (cannabidiol) are the primary cannabinoids in cannabis that interact with the body’s own endocannabinoid system , which plays a role in regulating mood, fear, and stress responses.

Treatment 96

Treatment Clinical Trials Marijuana Sleep 96

Veriheal

MAY 26, 2022

Patients around the world are in need of natural, alternative medical solutions, and Realm of Caring (RoC) is on a mission to serve them. RoC also works to increase patients’ access to medical cannabis by helping U.S. To date, Veriheal’s global team has helped hundreds of thousands of patients gain access to medical cannabis.

Advocacy 98

Advocacy Patients Clinical Trials Education 98

Project CBD

JANUARY 23, 2023

Cannabis and immunotherapy have both gained traction in the oncology field in recent years — one to help treat symptoms and the other as a gentler alternative to chemotherapy — but there’s been some concern that for cancer patients using both, the former could interfere with the latter. THC for Tumors?

Clinical Trials 130

Clinical Trials Treatment Patients Cannabinoids 130

Veriheal

FEBRUARY 11, 2021

Cannabis has been identified as a potentially effective strategy to decrease opiate usage and the survey wanted to determine how the use of medical cannabis affects opioid prescription usage among patients with chronic pain. They conducted an online survey of patients from three medical practice sites.

Chronic Pain 93

Chronic Pain Patients Clinical Trials Treatment 93

The Cannigma

FEBRUARY 2, 2021

In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. Of these consumers, over half said the drug had a beneficial clinical effect on their condition. Patients can also access CBD products without a prescription through local pharmacies.

Patients 89

Patients Clinical Trials Research and Development Treatment 89